Home Pneumonia Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial 2 Dec 2021 The Lancet Share on FacebookShare Share on XTweet
The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results
The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results
China pneumonia: Hong Kong authorities take low-key approach to passengers arriving in Hong Kong on Wuhan trains
Carbon black Carbon Black Market Trends, Size, Share, Growth Status, and Forecast 2024 to 2032 3 May 2024 8
Carbon emission trading Laconic Partners with Emsurge to Provide the Carbon Market A Single Source for Carbon Pricing Data USA - English 3 Apr 2024 1
Brighton vs Brentford Brighton come back, beat Brentford through Gross, teen Hinshelwood 6 Dec 2023 3
Harta share price Hartalega's target prices, ratings suffer on lower ASPs, one-off prosperity tax 9 Feb 2022 1